British biopharmaceutical company: Summit Therapeutics (SMMT)

Summit Therapeutics plc (NASDAQ: SMMT), formerly known as Summit Corporation plc, was founded in 2003 and changed to its current name in February 2015, Headquartered in the UK Abingdon， 76 full-time employees Biopharmaceutical Company , focusing on the discovery, development and commercialization of new drugs for treating rare diseases and infectious diseases in the UK and North America.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/smmt.html

Summit Therapeutics (SMMT)

Summit Therapeutics plc is carrying out a clinical plan for genetic disease Duchenne muscular dystrophy (DMD) and infectious disease caused by clostridium (CDI). The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/smmt.html

SMMT focuses on the research and correlation of related diseases (dwarfism, dwarfism) caused by muscular dystrophy (DMD) gene mutation Research and development of therapeutic drugs The two main strategic directions of the company are: research and treatment of Duchenne muscular dystrophy (a fatal genetic muscular atrophy disease) and infectious diseases caused by clostridium. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/smmt.html

The first DMD product candidate drug of Summit Therapeutics is ezutromid, an oral small molecule, which is in phase II clinical trial; The preferred candidate product for CDI is ridinilazole, a small molecule antibiotic for oral administration, which has completed the Phase II clinical trial. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/smmt.html

Summit Therapeutics has established a strategic alliance with Oxford University to develop muscle dystrophy protein regulators. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/smmt.html

Summit Therapeutics (SMMT) US equity investment

Summit Therapeutics plc (NASDAQ: SMMT) was listed on the NASDAQ Stock Exchange on March 5, 2015, with an issue price of $9.9/common stock. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/smmt.html

• reference material: